Daniel Rosan was appointed President of Ascidian Therapeutics in July 2026, retaining his existing responsibilities as Chief Financial Officer and Chief Business Officer of the biotechnology company.
In the expanded role he works alongside the executive leadership team and the Board of Directors to advance the company strategic priorities during the search for a new Chief Executive Officer. His remit spans finance, business development and corporate strategy for the RNA exon editing developer.
Rosan joined Ascidian Therapeutics as a senior finance and business leader and has represented the company at industry forums covering finance and accounting in the bioscience sector.
Facts compiled by Executive Moves from publicly available news and press releases on 22 July 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you Daniel Rosan?
This is a Light profile, auto-generated from public news coverage. Claim it to verify your bio, add a photo and links, and control how your career is represented on Executive Moves.
Claim this profile →
